Skip to main content

Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma.

Publication ,  Conference
Satwani, P; Jin, Z; Martin, PL; Bhatia, M; Garvin, JH; George, D; Chaudhury, S; Talano, J; Morris, E; Harrison, L; Sosna, J; Peterson, M ...
Published in: Leukemia
February 2015

The outcome of children, adolescents and young adults (CAYA) with poor-risk recurrent/refractory lymphoma is dismal (⩽30%). To overcome this poor prognosis, we designed an approach to maximize an allogeneic graft vs lymphoma effect in the setting of low disease burden. We conducted a multi-center prospective study of myeloablative conditioning (MAC) and autologous stem cell transplantation (AutoSCT), followed by a reduced intensity conditioning (RIC) and allogeneic hematopoietic cell transplantation (AlloHCT) in CAYA, with poor-risk refractory or recurrent lymphoma. Conditioning for MAC AutoSCT consisted of carmustine/etoposide/cyclophosphamide, RIC consisted of busulfan/fludarabine. Thirty patients, 16 Hodgkin lymphoma (HL) and 14 non-Hodgkin lymphoma (NHL), with a median age of 16 years and median follow-up of 5years, were enrolled. Twenty-three patients completed both MAC AutoSCT and RIC AlloHCT. Allogeneic donor sources included unrelated cord blood (n=9), unrelated donor (n=8) and matched siblings (n=6). The incidence of transplant-related mortality following RIC AlloHCT was only 12%. In patients with HL and NHL, 10 year EFS was 59.8% and 70% (P=0.613), respectively. In summary, this approach is safe, and long-term EFS with this approach is encouraging considering the poor-risk patient characteristics and the use of unrelated donors for RIC AlloHCT in the majority of cases.

Duke Scholars

Published In

Leukemia

DOI

EISSN

1476-5551

Publication Date

February 2015

Volume

29

Issue

2

Start / End Page

448 / 455

Location

England

Related Subject Headings

  • Young Adult
  • Treatment Outcome
  • Transplantation, Homologous
  • Transplantation, Autologous
  • Transplantation Conditioning
  • Recurrence
  • Prospective Studies
  • Prognosis
  • Lymphoma, Non-Hodgkin
  • Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Satwani, P., Jin, Z., Martin, P. L., Bhatia, M., Garvin, J. H., George, D., … Cairo, M. S. (2015). Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma. In Leukemia (Vol. 29, pp. 448–455). England. https://doi.org/10.1038/leu.2014.194
Satwani P, Jin Z, Martin PL, Bhatia M, Garvin JH, George D, Chaudhury S, Talano J, Morris E, Harrison L, Sosna J, Peterson M, Militano O, Foley S, Kurtzberg J, Cairo MS. Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma. Leukemia. 2015. p. 448–455.

Published In

Leukemia

DOI

EISSN

1476-5551

Publication Date

February 2015

Volume

29

Issue

2

Start / End Page

448 / 455

Location

England

Related Subject Headings

  • Young Adult
  • Treatment Outcome
  • Transplantation, Homologous
  • Transplantation, Autologous
  • Transplantation Conditioning
  • Recurrence
  • Prospective Studies
  • Prognosis
  • Lymphoma, Non-Hodgkin
  • Immunology